228 related articles for article (PubMed ID: 10632366)
1. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
3. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.
Xie M; Zhou L; Hu T; Yao M
Anticancer Drugs; 2007 Apr; 18(4):459-66. PubMed ID: 17351398
[TBL] [Abstract][Full Text] [Related]
6. Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films.
Liu R; Wolinsky JB; Walpole J; Southard E; Chirieac LR; Grinstaff MW; Colson YL
Ann Surg Oncol; 2010 Apr; 17(4):1203-13. PubMed ID: 19957041
[TBL] [Abstract][Full Text] [Related]
7. Prevention of local tumor growth with paclitaxel-loaded microspheres.
Azouz SM; Walpole J; Amirifeli S; Taylor KN; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2008 May; 135(5):1014-21. PubMed ID: 18455578
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
9. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin.
Mo Y; Lim LY
J Control Release; 2005 Nov; 108(2-3):244-62. PubMed ID: 16213056
[TBL] [Abstract][Full Text] [Related]
11. Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies.
Li KW; Dang W; Tyler BM; Troiano G; Tihan T; Brem H; Walter KA
Clin Cancer Res; 2003 Aug; 9(9):3441-7. PubMed ID: 12960135
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK; Fleming GF; Markman M; Bailey HH
Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
[TBL] [Abstract][Full Text] [Related]
13. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer.
Le Visage C; Rioux-Leclercq N; Haller M; Breton P; Malavaud B; Leong K
J Urol; 2004 Mar; 171(3):1324-9. PubMed ID: 14767342
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
Liang HF; Chen CT; Chen SC; Kulkarni AR; Chiu YL; Chen MC; Sung HW
Biomaterials; 2006 Mar; 27(9):2051-9. PubMed ID: 16307794
[TBL] [Abstract][Full Text] [Related]
16. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
18. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
19. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres.
Tzafriri AR; Lerner EI; Flashner-Barak M; Hinchcliffe M; Ratner E; Parnas H
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):826-34. PubMed ID: 15701873
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Springate CM; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
